San Diego, CA, United States of America

Beverly Knight

USPTO Granted Patents = 1 

Average Co-Inventor Count = 15.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):

Title: Beverly Knight: Innovator in Autoimmune Treatment

Introduction

Beverly Knight is a prominent inventor based in San Diego, CA (US). She has made significant contributions to the field of pharmaceutical sciences, particularly in the treatment of autoimmune diseases. Her innovative work has led to the development of a patented composition that holds promise for patients suffering from related disorders.

Latest Patents

Beverly Knight holds 1 patent for her invention titled "Compositions of peptide inhibitors of Interleukin-23 receptor." This invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof. The corresponding pharmaceutical compositions, methods, and uses are aimed at treating autoimmune inflammation and related diseases and disorders.

Career Highlights

Throughout her career, Beverly has worked with notable companies in the pharmaceutical industry, including Janssen Pharmaceutica NV and Protagonist Therapeutics, Inc. Her experience in these organizations has allowed her to refine her expertise and contribute to groundbreaking research in her field.

Collaborations

Beverly has collaborated with esteemed colleagues such as Giustino Di Pretoro and Dajun Sun. These partnerships have further enhanced her research and development efforts, leading to advancements in therapeutic solutions.

Conclusion

Beverly Knight's innovative work in the pharmaceutical industry exemplifies her commitment to improving treatment options for autoimmune diseases. Her contributions through her patent and collaborations highlight her role as a key figure in medical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…